Publikationen in Zusammenarbeit mit Forschern von Universidade da Coruña (9)

2024

  1. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

2023

  1. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients

    BMC Health Services Research, Vol. 23, Núm. 1

  2. Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 556-565

  3. Influence on sputum microbiology with CFTR modulator (tezacaftor-ivacaftor) in adult patients with cystic fibrosis: Multicenter study

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 3, pp. 193-195

2022

  1. Real Life With Tezacaftor and Ivacaftor in Adult Patients With Cystic Fibrosis: Spanish Multicenter Study

    Archivos de Bronconeumologia, Vol. 58, Núm. 9, pp. 672-674

2021

  1. Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)

    Drugs

  2. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study

    Drugs, Vol. 81, Núm. 15, pp. 1763-1774

2019

  1. The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease

    Clinical Cardiology, Vol. 42, Núm. 3, pp. 346-351

2018

  1. Cost of hospitalizations due to exacerbation in patients with non-cystic fibrosis bronchiectasis

    Respiration, Vol. 96, Núm. 5, pp. 406-416